Novo Nordisk’s Wegovy Outshines Eli Lilly’s Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death

All NewsSeptember 2, 2025

Novo Nordisk’s Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent